We propose that DNA hypermethylation of the keratin 18 gene may serve as a biomarker for diagnosis of brain metastasis of breast cancer or can be used to evaluate whether breast cancer patients with brain metastasis are potential candidates and would benefit from hypomethylating agent treatment. This evidence concerns the gene KRT18 and breast carcinoma.